DOP13: Clinical and endoscopic response to ustekinumab in Crohn’s Disease: Week 16 interim analysis of the STARDUST trialECCO'20 Vienna
2020
DOP15: An evaluation of the exposure-efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s Disease: Pharmacokinetic findings from VISIBLE 2ECCO'20 Vienna
2020
DOP16: Transmural healing with vedolizumab in patients with active Crohn’s DiseaseECCO'20 Vienna
2020
DOP18: Impact of adherence to anti- tumor necrosis factor therapy on clinical outcomes in Crohn's Disease: A nationwide population-based studyECCO'20 Vienna
2020
DOP19: Real-world healthcare resource utilisation among patients with Inflammatory Bowel Disease administered vedolizumab for 6 monthsECCO'20 Vienna
2020
DOP20: Can lifestyle and psychosocial factors predict flares of IBD; an exploratory study using telemedicineECCO'20 Vienna
2020
DOP21: Time to first treatment with biologic agents for Ulcerative Colitis and Crohn’s Disease across four Nordic countries: Results from the TRINordic studyECCO'20 Vienna
2020
DOP22: Certification of Integral Care IBD Units: Evaluation of a certification program (CUE)ECCO'20 Vienna
2020
DOP25: Medication use and comorbidities among elderly as compared to younger patients with Inflammatory Bowel Disease in the TARGET-IBD CohortECCO'20 Vienna
2020
DOP26: Real-life dosing patterns and concomitant drug use among ustekinumab-treated patients with Crohn’s DiseaseECCO'20 Vienna
2020
DOP27: Transanal minimally invasive surgery (TAMIS) – A noval approach for treatment of pouch failureECCO'20 Vienna
2020
DOP37: Neoplastic lesions outside diseased area in Inflammatory Bowel Disease patients: A National Cohort StudyECCO'20 Vienna
2020
DOP38: Prevalence of fatigue in a severe Inflammatory Bowel Disease cohort highly exposed to biologicsECCO'20 Vienna
2020
DOP41: Low grade dysplasia prognosis and predictive factors for advanced neoplasia progression in the 21st century – a large multi-centre retrospective cohort studyECCO'20 Vienna
2020
DOP42: Impact of discontinuing thiopurines at anti-TNF initiation in Inflammatory Bowel Disease: A nationwide Danish cohort studyECCO'20 Vienna
2020